Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
BACKGROUND
Low-molecular-weight iron dextran (CosmoFer) is the only form of parenteral iron that can be administered as a total dose infusion (TDI) in the United Kingdom (UK). This study aimed to evaluate the safety and efficacy of TDI CosmoFer in comparison to intravenous iron sucrose infusion (Venofer) in patients with chronic kidney disease (CKD).


RESULTS
A retrospective study of outpatients with CKD undergoing intravenous TDI CosmoFer or Venofer infusion was conducted at Salford Royal Hospital and Sunderland Royal Hospital. A total of 979 doses of CosmoFer and 504 doses of Venofer were administered. There were three minor adverse events in patients receiving CosmoFer compared with one minor event in a Venofer treated patient. There were no anaphylactoid-type reactions in either group. Serum haemoglobin, ferritin and transferrin saturation (TSAT) improved significantly 4-6 months postinfusion in both treatment groups.


CONCLUSIONS
TDI CosmoFer is an efficacious method of replenishing iron stores in CKD patients in an outpatient setting. Furthermore, TDI CosmoFer is safe and not associated with an increase in adverse events compared to Venofer.
Sinha
Smeeta
S
Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, UK.
Chiu
Diana Y Y
DY
Peebles
George
G
Kolakkat
Shabeer
S
Lamerton
Elizabeth
E
Fenwick
Sean
S
Kalra
Philip A
PA
D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007262:Infusions, Intravenous; D007505:Iron-Dextran Complex / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D012189:Retrospective Studies; D013395:Sucrose / Q000008:administration & dosage / Q000009:adverse effects*
D005290:Ferric Compounds; D006397:Hematinics; D013395:Sucrose; D007505:Iron-Dextran Complex; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid